Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | GJB2 | P29033 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260974 | 1.00 | GBA1 (0.61) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL22260973 | 1.00 | GBA1 (0.61) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL22260975 | 1.00 | GBA1 (0.61) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL17848812 | 1.00 | GBA1 (0.61) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL28340503 | 1.00 | GBA1 (0.61) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL8630393 | 0.92 | SLC2A1 (0.54) | GBA1SLC2A1GJB2MAPK1 | |
| SCHEMBL23646744 | 0.89 | GBA1 (0.59) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL10715427 | 0.89 | GBA1 (0.59) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL4351721 | 0.89 | GBA1 (0.59) | GBA1SLC2A1GJB2MAPK1LGALS8 | |
| SCHEMBL4595842 | 0.89 | GBA1 (0.59) | GBA1SLC2A1GJB2MAPK1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | GBA1 1025/4885SLC2A1 4247/4885GJB2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.